scholarly journals Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Ju-Yeon Kim ◽  
Eun Jung Jung ◽  
Jae-Myung Kim ◽  
Han Shin Lee ◽  
Seung-Jin Kwag ◽  
...  
Keyword(s):  
Initial Treatment ◽  
Univariate Analysis ◽  
Axillary Lymph Node Metastasis ◽  
Post Treatment ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cancer Prognosis ◽  
Axillary Lymph ◽  
Platelet To Lymphocyte Ratio ◽  
Free Survival ◽  
Lymphocyte Ratio

Abstract Background We aimed to identify whether neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are more useful predictors after initial intention to treat than at the time of diagnosis. Methods We collected the medical data of 533 patients. The results of the peripheral blood sampling before the primary treatments were labeled as initial cohort, and those obtained between 24 and 36 months after initial treatment were defined as the 2nd cohort. Delayed metastasis has been defined as distant metastasis 2 years after treatment, and survival outcome was estimated and compared across groups. Results Median follow-up duration was 74 months (24–162 months), and 53 patients experienced delayed metastasis. In univariate analysis, metastasis-free survival, patient age at diagnosis, tumor size, axillary lymph node metastasis, HER-2 status, initial NLR and PLR, and 2nd NLR and PLR were found to be significantly associated with delayed metastasis. However, in multivariate analysis, only the 2nd NLR and PLR were found to be significantly associated with delayed metastasis, excluding initial NLR and PLR. Metastasis-free survival was analyzed through the pattern changes of NLR or PLR. The results revealed that patients with continued low NLR and PLR values at pre- and post-treatment (low initial values and 2nd values) showed a significantly better prognosis than those with a change in value or continued high NLR and PLR. Conclusions We identified that patients with persistent high NLR and PLR after initial treatment have significant worse prognosis in terms of late metastasis. Therefore, these results suggest that NLR and PLR are more useful in predicting prognosis post-treatment.

scholarly journals Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis

2020 ◽  
Author(s):  
Ju-Yeon Kim ◽  
Eun Jung Jung ◽  
Jae-Myung Kim ◽  
Han Shin Lee ◽  
Seung-Jin Kwag ◽  
...  
Keyword(s):  
Initial Treatment ◽  
Univariate Analysis ◽  
Axillary Lymph Node Metastasis ◽  
Post Treatment ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cancer Prognosis ◽  
Axillary Lymph ◽  
Platelet To Lymphocyte Ratio ◽  
Free Survival ◽  
Lymphocyte Ratio

Abstract Background: We aimed to identify whether neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are more useful predictors after initial intention to treat than at the time of diagnosis.Methods: We collected the medical data of 533 patients. The results of the peripheral blood sampling before the primary treatments were labeled as initial cohort, and those obtained between 24 and 36 months after initial treatment were defined as the 2nd cohort. Delayed metastasis has been defined as distant metastasis 2 years after treatment, and survival outcome was estimated and compared across groups. Results: Median follow-up duration was 74 months (24–162 months), and 53 patients experienced delayed metastasis. In univariate analysis, metastasis-free survival, patient age at diagnosis, tumor size, axillary lymph node metastasis, HER-2 status, initial NLR and PLR, and 2nd NLR and PLR were found to be significantly associated with delayed metastasis. However, in multivariate analysis, only the 2nd NLR and PLR were found to be significantly associated with delayed metastasis, excluding initial NLR and PLR. Metastasis-free survival was analyzed through the pattern changes of NLR or PLR. The results revealed that patients with continued low NLR and PLR values at pre- and post-treatment (low initial values and 2nd values) showed a significantly better prognosis than those with a change in value or continued high NLR and PLR. Conclusions: We identified that patients with persistent high NLR and PLR after initial treatment have significant worse prognosis in terms of late metastasis. Therefore, these results suggest that NLR and PLR are more useful in predicting prognosis post-treatment.

scholarly journals Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis

2020 ◽  
Author(s):  
Ju-Yeon Kim ◽  
Eun Jung Jung ◽  
Jae-Myung Kim ◽  
Han Shin Lee ◽  
Seung-Jin Kwag ◽  
...  
Keyword(s):  
Initial Treatment ◽  
Univariate Analysis ◽  
Post Treatment ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cancer Prognosis ◽  
Platelet To Lymphocyte Ratio ◽  
Free Survival ◽  
Lymphocyte Ratio ◽  
Intention To Treat ◽  
Initial Cohort

Abstract Background We aimed to determine whether neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are more useful predictors after initial intention to treat than at the time of diagnosis.Methods We collected the medical records of 533 patients. The results of the peripheral blood sampling before the primary treatments were labeled as initial cohort, and those obtained between 24 and 36 months after initial treatment were defined as the 2nd cohort. Delayed metastasis has been defined as distant metastasis 2 years after treatment, and survival outcome was estimated and compared across groups.Results Median follow-up duration was 74 months (24–162 months), and 53 patients experienced delayed metastasis. In univariate analysis, metastasis-free survival, patient age at diagnosis, tumor size, lymph node metastasis, HER-2 status, initial NLR and PLR, and 2nd NLR and PLR were found to be significantly associated with delayed metastasis. However, in multivariate analysis, only the 2nd NLR and PLR were found to be significantly associated with delayed metastasis, excluding initial NLR and PLR. Metastasis-free survival was analyzed through the pattern changes of NLR or PLR. The results revealed that patients with continued low NLR and PLR values at pre- and post-treatment (low initial values and 2nd values) showed a significantly better prognosis than those with a change in value or continued high NLR and PLR.Conclusions We identified that patients with persistent high NLR and PLR after initial treatment have significant worse prognosis in terms of late metastasis. Therefore, these results suggest that NLR and PLR are more useful in predicting prognosis post-treatment.

scholarly journals Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis

2020 ◽  
Author(s):  
Ju-Yeon Kim ◽  
Eun Jung Jung ◽  
Jae-Myung Kim ◽  
Han Shin Lee ◽  
Seung-Jin Kwag ◽  
...  
Keyword(s):  
Initial Treatment ◽  
Univariate Analysis ◽  
Post Treatment ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cancer Prognosis ◽  
Platelet To Lymphocyte Ratio ◽  
Free Survival ◽  
Lymphocyte Ratio ◽  
Intention To Treat ◽  
Initial Cohort

Abstract Background: We aimed to determine whether neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are more useful predictors after initial intention to treat than at the time of diagnosis.Methods: We collected the medical records of 533 patients. The results of the peripheral blood sampling before the primary treatments were labeled as initial cohort, and those obtained between 24 and 36 months after initial treatment were defined as the 2nd cohort. Delayed metastasis has been defined as distant metastasis 2 years after treatment, and survival outcome was estimated and compared across groups.Results: Median follow-up duration was 74 months (24–162 months), and 53 patients experienced delayed metastasis. In univariate analysis, metastasis-free survival, patient age at diagnosis, tumor size, lymph node metastasis, HER-2 status, initial NLR and PLR, and 2nd NLR and PLR were found to be significantly associated with delayed metastasis. However, in multivariate analysis, only the 2nd NLR and PLR were found to be significantly associated with delayed metastasis, excluding initial NLR and PLR. Metastasis-free survival was analyzed through the pattern changes of NLR or PLR. The results revealed that patients with continued low NLR and PLR values at pre- and post-treatment (low initial values and 2nd values) showed a significantly better prognosis than those with a change in value or continued high NLR and PLR.Conclusions: We identified that patients with persistent high NLR and PLR after initial treatment have significant worse prognosis in terms of late metastasis. Therefore, these results suggest that NLR and PLR are more useful in predicting prognosis post-treatment.

scholarly journals Hematologic Markers as Prognostic Factors in Nonmetastatic Esophageal Cancer Patients under Concurrent Chemoradiotherapy

2019 ◽  
Vol 2019 ◽  
pp. 1-11
Author(s):  
Yi-Feng Wu ◽  
Sung-Chao Chu ◽  
Bee-Song Chang ◽  
Yi-Tso Cheng ◽  
Tso-Fu Wang
Keyword(s):  
Esophageal Cancer ◽  
Poor Prognosis ◽  
Concurrent Chemoradiotherapy ◽  
Univariate Analysis ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cancer Prognosis ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Platelet Counts ◽  
High Local Recurrence Rate

Nonmetastatic esophageal cancer can demonstrate a high local recurrence rate even under the standard treatment. We evaluated platelet counts before and after concurrent chemoradiotherapy (CCRT), neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio for predicting esophageal cancer prognosis under CCRT. Newly diagnosed patients with esophageal cancer (stages IA–IIIC) who underwent CCRT during January 2013–December 2017 were enrolled. The data were collected retrospectively. Overall survival (OS), time to progressive disease (TPD), and time to metastasis (TM) were recorded for indicating prognosis. Kaplan–Meier curves were plotted and univariate and multivariate analyses were performed. In total, 105 patients were enrolled. The stages of esophageal cancer and surgery were associated with prognosis (i.e., OS, TPD, and TM). Based on TPD and TM, women had better prognosis than men. In the univariate analysis, high pre- and post-CCRT platelet counts (>300,000/μL), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) as well as low lymphocyte percentage were significantly associated with poor prognosis. However, in the multivariate analysis, only post-CCRT high platelet count (>300,000/μL) remained significantly associated with poor prognosis (P = .041, .045, and .023 for OS, TPD, and TM, respectively). Poor prognosis was observed in patients with high platelet counts, PLR, NLR, and low lymphocyte percentage. Surgery was an independent factor predicting better prognosis. Our findings may have clinical significance with regard to therapeutic decision-making.

Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy

Immunotherapy ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 785-798
Author(s):  
Adi Kartolo ◽  
Ryan Holstead ◽  
Sidra Khalid ◽  
Jeffrey Emack ◽  
Wilma Hopman ◽  
...  
Keyword(s):  
Overall Survival ◽  
Potential Role ◽  
Progression Free Survival ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cancer Type ◽  
Small Cell Lung ◽  
Platelet To Lymphocyte Ratio ◽  
Free Survival ◽  
Lymphocyte Ratio ◽  
Cancer Types

Aim: To examine neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in prognosticating immunotherapy efficacy. Methods: A retrospective study of 156 patients with metastatic melanoma and non-small-cell lung cancer on PD-1 inhibitors. Results: Baseline NLR ≥5 was associated with worse progression-free survival (hazard ratio [HR]: 1.53; 95% CI: 1.01–2.31; p = 0.043) but nonsignificant worse overall survival trend (HR: 1.51; 95% CI: 0.98–2.34; p = 0.064). PLR ≥200 was associated with worse overall survival (HR: 1.94; 95% CI: 1.29–2.94; p = 0.002) and worse progression-free survival (HR: 1.894; 95% CI: 1.27–2.82; p = 0.002). NLR or PLR are prognosticating factors regardless of cancer types, with PLR having a stronger association with outcomes than NLR. Conclusion: High baseline NLR or PLR (alone and combined) were associated with worse immunotherapy efficacy regardless of cancer type, indicating their potential role as an agnostic marker for immunotherapy efficacy.

Impact of preoperative neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) on overall survival or recurrence free survival in muscle-invasive bladder cancer at cystectomy.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17050-e17050
Author(s):  
Scott Dawsey ◽  
Iris Yeong- Fung Sheng ◽  
Moshe Chaim Ornstein ◽  
Wei Wei ◽  
Byron H Lee ◽  
...  
Keyword(s):  
Overall Survival ◽  
Complete Blood Count ◽  
Cleveland Clinic ◽  
Neutrophil To Lymphocyte Ratio ◽  
Recurrence Free Survival ◽  
Platelet To Lymphocyte Ratio ◽  
Free Survival ◽  
Lymphocyte Ratio ◽  
Molecular Features ◽  
Markers Of Inflammation

e17050 Background: The role of Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR) in prognostication of MIBC is not clearly understood. There is growing evidence that, as markers of inflammation, they may have prognostic utility in MIBC at radical cystectomy (RC). Methods: We performed a retrospective analysis of MIBC patients who underwent RC at the Cleveland Clinic from 2/2015 to 1/2018. 84 patients were identified who were either diagnosed with TaN0M0 treated with Neoadjuvant Chemotherapy (NAC) or T1-T4N0M0 disease treated with or without NAC. For NAC, 27 patients received gemcitabine and cisplatin, 2 patients received gemcitabine and carboplatin, 4 patients received unknown regimen, and 3 patients received MVAC. Of the patients, there were 1 with Ta, 34 with T1, 44 with T2, 1 with T3 and 4 with T4 disease. Complete Blood Count with Differential closest to or on the day of resection was used. NLR and PLR were calculated by dividing Absolute Neutrophil Count and Platelet Count by the Absolute Lymphocyte Count, respectively. PLR and NLR were dichotomized at the median. Outcomes were analyzed via Kruskal-Wallis test. Results: Median follow up of patients was 28.8 months. Median NLR and PLR were 15.7 and 263, respectively. Mean NLR and PLR were 18.9 and 310, respectively. NLR and PLR did not correlate with overall survival, recurrence free survival, T or N stage post resection, or pathological response. Females were found to have a higher NLR than males. Conclusions: Contrary to previous reports, our study did not find any prognostic value of NLR and PLR in MIBC patients at RC. Further evaluation of PLR and NLR in MIBC and correlation with molecular features may help understand its potential prognostic role in patients undergoing surgical resection.

Combined Plasma Fibrinogen and Neutrophil Lymphocyte Ratio in Ovarian Cancer Prognosis May Play a Role?

2018 ◽  
Vol 28 (5) ◽  
pp. 939-944 ◽  
Author(s):  
Claudia Marchetti ◽  
Alessia Romito ◽  
Angela Musella ◽  
Giulia Santo ◽  
Innocenza Palaia ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Progression Free Survival ◽  
Neutrophil To Lymphocyte Ratio ◽  
Cancer Prognosis ◽  
Response To Treatment ◽  
Debulking Surgery ◽  
Free Survival ◽  
Lymphocyte Ratio ◽  
Gynecology And Obstetrics ◽  
The Absolute

ObjectivesIn ovarian cancer (OC), approximately 70% will relapse within 12 months from diagnosis; inflammation plays an important role in cancer initiating and progression; thus, a combination of neutrophil-to-lymphocyte ratio (NLR) and fibrinogen (F-NLR) has been proposed as prognostic marker in several tumors. The aim of our study was to investigate the correlation between NLR, fibrinogen, and F-NLR and survival in OC population.MethodsPatients with diagnosis of OC admitted to our institute between 2011 and 2016 were included. Data about pretreatment complete blood count were collected. Neutrophil-to-lymphocyte ratio was defined as the absolute neutrophil count divided by the absolute lymphocyte count; the F-NLR score was 0 for low NLR and fibrinogen, 1 for low NLR and high fibrinogen, or, conversely, 2 for both high markers. We correlated this index with progression-free survival.ResultsA total of 94 patients were enrolled. Median age at diagnosis was 55 (34–83) years; more than 80% of patients presented International Federation of Gynecology and Obstetrics stage III–IV at diagnosis, and 72 (77%) presented high-grade serous histology. Primary debulking surgery was performed in 57 women (60%), whereas 37 (40%) underwent interval debulking surgery.Mean serum NLR was 5.25 ± 5.37, and mean serum fibrinogen value was 4.19 ± 0.97 g/L. The median follow-up time was 27 months (range, 8–60 months). All patients with F-NLR value of 2 presented advanced disease compared with 64% of those with F-NLR of 0 (P< 0.031); these patients more frequently required neoadjuvant chemotherapy (P< 0.003) and more often had platinum-resistant disease (P< 0.022). Patients with high F-NLR presented worse progression-free survival than did patients with low F-NLR (12 vs 42 months, respectively,P= 0.023).ConclusionsCombining NLR and fibrinogen levels could be used as a factor for prediction of prognosis and response to treatment in patients affected with OC.

scholarly journals 362 Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with clinical outcomes to tislelizumab monotherapy in patients with previously treated advanced hepatocellular carcinoma

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A389-A389
Author(s):  
Philippe Merle ◽  
Helena Verdaguer Mata ◽  
Congying Xie ◽  
Richard Hubner ◽  
Yong Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Informed Consent ◽  
Post Treatment ◽  
Neutrophil To Lymphocyte Ratio ◽  
Advanced Hepatocellular Carcinoma ◽  
Platelet To Lymphocyte Ratio ◽  
Treatment Change ◽  
Advanced Hcc ◽  
Lymphocyte Ratio ◽  
Previously Treated

BackgroundTislelizumab, an anti-PD-1 monoclonal antibody, demonstrated clinical activity and was well-tolerated in patients with previously treated advanced hepatocellular carcinoma (HCC) in the Phase 2 RATIONALE-208 study (NCT03419897). We explored whether baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) or their post-treatment change correlated with clinical efficacy of tislelizumab treatment.MethodsEligible patients (>18 years) who had received ≥1 prior line of systemic therapy for advanced HCC were administered open-label tislelizumab (200 mg) intravenously every 3 weeks until no further clinical benefit was observed. NLR and PLR were assessed using peripheral blood samples collected at baseline, Cycle 2 Day 1 (C2D1), C3D1, and C4D1. Survival analysis (progression free survival [PFS] and overall survival [OS]) was conducted by Kaplan-Meier method and survival rate at risk was compared by log rank test. Logistic regression was used to analyze association of post-treatment change of NLR or PLR with objective response rate (ORR). In the baseline analysis, median NLR or PLR in this study was used as a cut-off. All statistical analysis results are post-hoc exploratory and thereby p values are descriptive.ResultsOverall, 249 patients were enrolled, of which 249, 234, 203, and 186 patients had evaluable NLR and PLR data at baseline, C2D1, C3D1, and C4D1, respectively. Analysis of NLR at baseline, using median NLR (3.2) as cut-off, demonstrated higher OS (p=0.0024) and PFS (p=0.071) in NLR-low versus NLR-high groups (median OS [mOS]:17.4 versus 9.9 months; median PFS [mPFS]: 2.8 versus 1.5 months). Analysis of PLR at baseline, using median PLR (141.4) as cut-off, showed higher OS (p=0.0085) and PFS (p<0.0001) in PLR-low versus PLR-high groups (mOS: 16.2 versus 10.8 months; mPFS: 2.8 versus 1.4 months). In post-treatment analysis, patients with decreased NLR or PLR at C2D1, C3D1 or C4D1 had higher ORR (table 1) and longer OS (figure 1) compared with patients with increased NLR or PLR at each timepoint.Abstract 362 Table 1Post-treatment decreases in NLR or PLR were associated with response to tislelizumab monotherapyAbstract 362 Figure 1Post-treatment decreases in NLR or PLR were associated with improved OS following tislelizumab monotherapyConclusionsIn patients with previously treated advanced HCC that received tislelizumab monotherapy, lower baseline NLR or PLR was associated with longer OS and PFS, and post-treatment decreases of NLR or PLR were associated with higher ORR and longer OS. These observations support NLR and PLR as potential prognostic biomarkers in patients with advanced HCC treated with tislelizumab and will be further investigated in an on-going Phase 3 study (NCT03412773).AcknowledgementsThis study is sponsored by BeiGene Ltd. Medical writing support for the development of this abstract, under direction of the authors, was provided by Claire White, PhD, and Kirsty Millar, MSc, of Ashfield MedComms, an Ashfield Health company, and was funded by BeiGene Ltd.Trial RegistrationNCT03419897Ethics ApprovalThis study was conducted according to the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines, the principles of informed consent and the requirements of the public registration of clinical trials. Written informed consent was obtained from each patient prior to screening. The protocol was approved by the institutional ethics committee and was monitored by the investigators and study sponsor.

scholarly journals Does Preoperative Serum Neutrophil To Lymphocyte Ratio (NLR), Platelet To Lymphocyte Ratio (PLR) And Lymphocyte To Monocyte Ratio (LMR) Predict Prognosis Following Radical Surgery For Pancreatic Adenocarcinomas? - Results of A Retrospective Study.

2021 ◽  
Author(s):  
Vikas Bachelal Gupta ◽  
Vikram Chaudhari ◽  
Shailesh V. Shrikhande ◽  
Manish S. Bhandare
Keyword(s):  
Overall Survival ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Tnm Stage ◽  
Neutrophil To Lymphocyte Ratio ◽  
Survival Outcomes ◽  
P Value ◽  
Platelet To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Lymphocyte To Monocyte Ratio

Abstract Background:Pretherapy serum neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and lymphocyte to monocyte ratio (LMR) have been shown to predict prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). However, the published literature is conflicting, hence we aimed to evaluate their role in predicting survival outcomes in operated patients of PDAC.Methods: A retrospective analysis was done of all operated cases of PDAC who underwent curative resection between 2011 to 2018. The pretherapy NLR, PLR and LMR were calculated and analyzed with respect to pathological and survival outcomes Results:134 operated patients were included. The median overall survival for NLR of less than 2, 2.7 and 5 was 30.8, 27.2 and 27.5 months and for NLR more than 2, 2.7 and 5 was 22.9, 21.6 and 21.5 months respectively and was statistically insignificant (p-value- 0.32, 0.91, 0.34 respectively). Similarly, the PLR was not significant for a cut off of 150 (p-value- 0.27) and LMR was not significant for a cut off of 2.8 (p-value- 0.13) and 4.8( p-value -0.11). On Univariate analysis age, CA 19-9, perineural invasion, margin positivity, lymph node positivity and TNM stage were found to have significant correlation with overall survival. However, on multivariate analysis, only TNM stage was found to be significant. Conclusion:The NLR, PLR and LMR do not correlate with overall survival in operated patients with PDAC in this study. A combination of inflammatory markers or their dynamic testing might probably achieve prognostic significance.

Sign in / Sign up

Export Citation Format

Share Document